Stack

I wonder what the anti GLP-1 people have to say about this

@DrCamRx Agree

Unpopular Opinion: Tirzepatide is a better choice for most people than Retatrutide. TRIUMPH-1 trial results prove it: Reta 4 mg: 19% weight loss at 80 weeks Tirz 10 mg: 19.5% weight loss at 72 weeks Reta is only superior at 9+ mg doses (25.9%) with far more side effects:

@Atlas_adjust @maxmarchione No?

@stackapp @maxmarchione Because they don't know any better?

Retatrutide phase 3 obesity trial just came out and the results are genuinely insane: - 28.3% bodyweight lost on 12mg over 80 weeks - 70.3 pounds on avg. or 31.9 kg - 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory) - 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients - 65.3% of 12mg patients dropped below the obesity BMI threshold - 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%) - significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP - no cardiac or liver signals Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time.

@pepguide @maxmarchione Yes

@stackapp @maxmarchione Assuming you’re saying this because Tirz does not increase resting heart rate like Reta does? I agree if so (and have had more success with Tirz than Reta)

@viktor__com @errettpeptides That someone is out there Viktor

@errettpeptides @stackapp first content hire at a biotech startup is really two jobs. the people who already make content and the people who can read a clinical study without flinching almost never overlap. the actual decision is which side you'd rather train.

Hiring our first content person at @stackapp. If you're in Austin, already make content, have a passion for health and wellness, want to learn biotech, and want to be part of a fast-moving team, DM me.

@ElevateBiohack good post

Retatrutide (Reta) reality check for the fitness crowd lol Everyone’s out here dropping “study says” links like it’s gospel. Higher doses = more fat loss, faster results, blah blah. But let’s actually read the room, or in this case, the study populations. These landmark trials were run on morbidly obese individuals with BMIs in the 35-40+ range, often with multiple comorbidities, sedentary lifestyles, and zero resistance training history. Not on lean fitness enthusiasts. Not on influencers grinding in the gym 5-6 days a week. Not on bodybuilders managing 10-15% body fat trying to get stage shredded. Your response to the drug is going to be wildly different if you’re already relatively lean, insulin sensitive, and lifting heavy. The marginal benefit of cranking doses into the stratosphere diminishes fast once you’re not starting from severe obesity. The side effect risk? It doesn’t diminish it often goes the other way. Just because a titration schedule exists doesn’t mean you’re obligated to follow it all the way to the top like a video game difficulty slider. Common sense still applies: •Start low, titrate slow •Listen to your body (appetite, energy, sleep, digestion, HR) •If you’re already leaning out nicely at 1-3.5mg… why chase 4-8mg or even 12-15mg just because some trial on 300+ lb patients went there? •Muscle preservation, training performance, and long-term metabolic health matter more than squeezing out every last pound of fat loss in 12 weeks. The fitness community loves to “optimize” everything into the ground. Sometimes the smartest optimization is… not doing the maximum tolerated dose just because a paper said so. This isn’t anti-Reta. This is pro-critical thinking. The drug is incredibly powerful. Respect it. Don’t treat it like a peptide buffet where more = always better. Your results at 10-12% body fat on maintenance calories + heavy lifting will not mirror a 400 lb patient on a 1500 calorie deficit. Different starting points = different optimal dosing. #Retatrutide #Reta #Tirzepatide #Semaglutide #GLP1 #Biohacking #PeptideTherapy #Fitness #Bodybuilding #WeightLoss #FatLoss #OptimizeDontOverdo #CommonSenseBiohacking #ElevateBiohack

@m_goes_distance the UAE and China are way ahead of the US We still have time to change this, but need to move NOW

the UAE might just win the biology/acc race and nobody in the US is talking about it - Mubadala Capital, Abu Dhabi's sovereign wealth fund, is writing $75M checks directly into longevity biotech - UAE longevity industry projected to surpass $23B by 2026. state backed. no apology. - zero personal tax, zero corporate tax, supportive regulatory environment. biotech founders are relocating. - clinical trials run faster and cheaper than anywhere in the West George Church told me on the podcast the US might eventually have to call upon UAE to catch up think about that for a second the most decorated biology professor at Harvard said the US might lose the biology race to a country that did not exist 50 years ago? science is never the problem, the system around it is

GLP-1s have been the biggest healthcare story of the last 3 years they also have one big problem people lose muscle alongside fat 4 biotech companies just read out phase 2 trials on drugs designed to fix exactly that Lilly. Regeneron. Scholar Rock. Veru. they are all showing great results in trials

@errettpeptides Join us!

Health and longevity will be the biggest market of all time

@m_goes_distance Banger

Demis Hassabis raised $2.1B to solve disease with AI. but zoom out and the picture gets wilder: - longevity startups attracted $8.5B in venture capital last year alone. more than double the year before - China now runs more clinical trials than the US. over 7,100 in 2024 versus 6,000. first-in-human trials launch faster and cheaper there. the data advantage is compounding - XPRIZE Healthspan is awarding $10M each to its top 10 finalists to run one-year clinical trials specifically designed to restore functional capacity in aging humans. results coming this year - Insilico Medicine ran an AI-designed drug through Phase 2 clinical trials and it worked. a longevity company just proved the AI drug discovery pipeline end to end. every major AI lab founder: Dario, Demis, Sam, have named longevity as a core motivation for their work and the people building it are moving faster than anyone expected bio/acc

@demishassabis @IsomorphicLabs Super exciting

I’ve always believed the No.1 application of AI should be to improve human health. That work started with AlphaFold, and now at @IsomorphicLabs with the mission to reimagine drug discovery and one day solve all disease! We are turbocharging that goal with $2.1B in new funding.

This is a lot bigger of a deal than most people are realizing Renaming PCOS to PMOS officially codes the condition as metabolic, not gynecological That single shift puts GLP-1s, metformin, and the entire metabolic toolkit on the treatment pathway PCOS affects ~10% of women of reproductive age The GLP-1 TAM just expanded by tens of millions overnight nice catch @mansizzzzle

Function just acquired SuppCo This is a really good move imo SuppCo was the first app I used that actually showed supplements being done the right way: trust layer, real data, aligned with the consumer not the brand Function is no longer just a testing company. they're building the loop

@m_goes_distance bio/acc

biotech will do more for humanity in the next 18 months than the last 50 years here is what the next 12-18 months carry: 1. aging becomes reversible - Life Biosciences reports results from the first ever human epigenetic reprogramming trial by end of 2026. if it works the entire category reprices overnight 2. your genome becomes your medical record-consumer grade sequencing is already at $1,100. by 2027 it is a standard intake form 3. personalized gene therapies become real - baby KJ proved a custom CRISPR therapy can be built for one person in 6 months. his doctors are now building the FDA pathway to do it for everyone 4. peptides go fully mainstream - 14 of 19 banned compounds are coming back to legal compounding. the grey market becomes a regulated industry with actual quality standards 5. psychedelics become first line treatment - Compass Pathways is weeks from the first ever FDA approval of a psychedelic drug. depression and PTSD treatment just changed permanently 6. AI designs drugs that work better than anything a human team has ever produced- Isomorphic Labs is pushing AI-designed molecules into human trials right now. results expected this year 7. BCIs move from medical to performance - Merge Labs, Neuralink, Synchron all pointed at the same target. the first healthy person gets an implant for cognitive enhancement and the waitlist forms immediately after bio/acc

Agree Trust will be the ultimate Moat in this market and the brands that get it right become the rails

@BrianSuttererMD @valthealth I think it shows confidence

What a weird thing for a CEO to post. Sounds like someone trying to cope with the threat of competition for once. I can’t wait to try out the new Fitbit air. $100 with great third party solutions to make it special like @valthealth